2017_SBRT_Course Book

Dose in relation to volume: OARs

Acceptable variation in Gy l i i i

Unacceptable variation in Gy ≥8*5.81=46.68 t le i ti i . .

Unacceptable variation EqD2 in Gy c e t le ri ti i y

αβ

D max in Gy

EqD2 in Gy

OAR

i n G y y i

3 3 3 3 2 3 3 3 3

8*5.5= 44 8*5.5= 44 8*5.5= 44 8*5 = 40 8*4= 32 8*4.75=38

74.8 . 74.8 74.8

<8*5.81=46.68 . .

≥81.9 .

Trachea/ MainBronchus

Heart §

t *

<8*6=48 <8*6=48

≥8*6=48 ≥8*6=48

≥86.4 ≥86.4

GreatVessels § t e sels * Esophagus SpinalCord & BrachialPlexus &

64 48

<8*5.44=43.52 . .

≥8*5.44=43.52 . .

≥73.6 .

>8*4=32

≥48

58.9 .

<8*5.17=41.36 . .

≥8*5.17=41.36 . .

≥ 67.7 6 .

External-PTV &

8*7.5= 60

126

<8*7.785=62.28 . .

≥134.2 .

≥8*7.785=62.28 . .

Lungs-CTV § ChestWall § - l §

*

V20Gy<6%

V20<10%

V20Gy≥10%

8*8.25=66

148.5

≥8*9=72

≥172.8

& for <0.5 cc § no restrictions are provided but recording of DVH data for toxicity evaluation is required EORTC 22113-0813-LungTech RTQA Guidelines t t i it l ti is r ir Catharina Cancer Centre guidelines

Adebahr S et al. BJR 2015, EORTC Lungtech trial

* Following Mangona, IJROBP 91(1) p124-132 2015, William Beaumont Hospital